Skip to main content
. 2020 Aug 19;38(28):3282–3293. doi: 10.1200/JCO.20.00256

FIG A2.

FIG A2.

Disease-free survival (DFS) by day 29 minimal residual disease (MRD) status. (A) Five-year DFS rates in the nelarabine group were 92.3% ± 2.9% in those with MRD < 0.1% and 83.5% ± 3.9% for those with MRD ≥ 0.1% (P = .0102). (B) Five-year DFS rates in the no nelarabine group were 89.0% ± 3.1% in those with MRD < 0.1% and 73.4% ± 4.3% in those with MRD ≥ 0.1% (P = .0003).